EMA approved 104 human medicines in 2025: what changed

EMA approved 104 human medicines in 2025: what changed

Key Takeaways

• EMA recommended 104 medicines for marketing authorisation in 2025, providing a consolidated snapshot of EU regulatory momentum.
• Thirty-eight of those medicines contained a new active substance that had never been authorised before, signalling continued innovation in the EU approval pathway.
• The 2025 readout serves as a regulatory catalyst reference for BD and investor teams monitoring EU approval timelines and first-in-class asset positioning.

IntelligenceRegulatory Impact▾

EMA decisions frame this story. Regulatory relevance is high for osteoporosis, with denosumab most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

EMA's 2025 human medicines update

In 2025, the EMA recommended 104 medicines for marketing authorisation. Of these 104 medicines, 38 had a new active substance which had never been authorised before, underscoring the agency's continued role in bringing novel therapies to European patients.

For teams searching for EMA approval data, the agency's 2025 human medicines summary serves as the primary entry point. Readers building tracking sheets or monitoring regulatory milestones will find the annual summary useful for cross-referencing individual product names, indications, and approval timelines.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for osteoporosis. Expect implications for pricing, access, and launch sequencing.

Regulatory context for catalyst tracking

The 2025 EMA readout bundles regulatory recommendations into a single authoritative reference. For BD and investor teams, this consolidated view enables identification of competitive milestones and regulatory catalysts tied to EU market access.

In January and February 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the granting of an EU-wide marketing authorisation for seven new medicines, reflecting ongoing approval activity in the opening months of the year.

IntelligenceStrategic Takeaways▾

EMA recommended 104 medicines for marketing authorisation in 2025 , providing a consolidated snapshot of EU regulatory momentum. Thirty-eight of those medicines contained a new active substance that had never been authorised before , signalling continued innovation in the EU approval pathway. The 2025 readout serves as a regulatory catalyst reference for BD and investor teams monitoring EU approval timelines and firs

Denosumab and bone-health indications

Denosumab (generic name DENOSUMAB-BMWO) is a RANK ligand (RANKL) inhibitor with indications in postmenopausal women with osteoporosis at high risk for fracture, men with osteoporosis at high risk for fracture, and glucocorticoid-induced osteoporosis in men and women at high risk for fracture. The molecule is referenced in the 2025 regulatory landscape as a significant reference product in bone-health treatment.

IntelligenceEvidence Quality▾

Grounded in 3 regulatory sources and 1 peer-reviewed source.

Clinical evidence and near-term watchpoints

Several active trials track denosumab efficacy and safety across bone-related indications. NCT04467983 is a Phase 4 trial (active, not recruiting) evaluating abaloparatide added to ongoing denosumab versus continued denosumab alone in postmenopausal osteoporosis, sponsored by Hospital for Special Surgery in New York. NCT06588153, also Phase 4 and active but not recruiting, examines the efficacy and safety of Prolia (denosumab) in participants with glucocorticoid-induced osteoporosis in mainland China, sponsored by Amgen.

NCT06811363 is enrolling by invitation at the University of Texas Southwestern Medical Center and addresses the contribution of bone to urine citrate in osteoporosis, while NCT03921060, a Phase 4 trial recruiting at the same institution, examines markers of osteoporosis in cystic fibrosis. These trials represent ongoing clinical evaluation in specialized populations and represent watchpoints for future regulatory and commercial activity.

Implications for pharma BD and investors

The 104-medicine total for 2025 signals a substantial EU approval calendar. The concentration of 38 new active substances within the 104-medicine cohort highlights the mix of novel and incremental approvals. For regulatory and BD teams, the annual summary provides a baseline for tracking EU approval momentum and identifying products entering the market.

Frequently Asked Questions